Brain injuries, dementia and other neurological problems are often noticed too late. The damage is irrevocable. ADX Neurosciences S.A. is committed to developing biomarkers that can detect, with a simple blood test, neurodegeneration in an early stage. The Flemish government supports the innovative research of this biotech company.
With the grant of 850,000 euros ADx can expand its global leadership position as an innovator in the field of neurobiological markers.
In what way will ADx use the money from the Flemish Government over the next two years?
- The fine-tuning of a blood test that can detect neurodegeneration in an early stage
- Exploring a new development platform to significantly shorten the time between discovery of a marker and its commercialization
- The detection and discovery of new markers that play a crucial role in the faltering communication between brain cells
Why does the Flemish Government support this innovative company?
In only 5 years, ADx acquired a good global position in the challenging field of brain diseases such as Alzheimer’s and Parkinson’s. ADX has also managed to launch, with a previous grant, two new markers, neurogranin and BACE1, in collaboration with Prof. Bart De Strooper (KU Leuven – VIB) and Prof. Sebastiaan Engelborghs (UA). Both of these tests will play an important role in the development of new drugs for Alzheimer’s disease. The Flemish Agency for Enterprise and Innovation (VLAIO) also gave the green light to this new, ambitious project.
Koen Dewaele, CEO ADX: “We are very pleased with this support! This strengthens our ambition to build a world-neurobiological company. Our new tests will help a better and quicker diagnosis and also assist pharmaceutical companies in their development of new drugs for neurological disorders such as Alzheimer’s, Parkinson’s and ALS. ”
